Case Report: Afatinib Treatment in a Patient With NSCLC Harboring a Rare EGFR Exon 20 Mutation

Unlike most other primary epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC), exon 20 insertions, comprising approximately 4% to 10% of all EGFR mutations, are generally considered to be resistant to EGFR tyrosine kinase inhibitors (TKIs). However, EGFR exon 20 i...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Front Oncol
Auteurs principaux: Zöchbauer-Müller, Sabine, Kaserer, Bettina, Prosch, Helmut, Cseh, Agnieszka, Solca, Flavio, Bauer, Markus Johann, Müllauer, Leonhard
Format: Artigo
Langue:Inglês
Publié: Frontiers Media S.A. 2021
Sujets:
Oncology
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7871906/
https://ncbi.nlm.nih.gov/pubmed/33575211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.593852
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires